-

Cardiawave is presenting the 30-day follow-up results from its “Valvosoft® Pivotal Study” on the treatment of severe symptomatic aortic valve stenosis

At the 73rd Annual Conference of the ACC (American College of Cardiology) April 6–8, 2024, Atlanta (GA)

LEVALLOIS-PERRET, France--(BUSINESS WIRE)--Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, will present the 30-day follow-up results for 60 patients enrolled in its European pivotal study to the 73rd annual conference of the American College of Cardiology in Atlanta, Georgia. This is a leading event in the cardiovascular medicine calendar, which brings together specialists from around the world to discuss the latest advances, research results and clinical innovations in the field of cardiology.

Prof. Eric Van Belle, cardiologist at Lille University Hospital, one of the principal investigators for the European pivotal study, commented: “I’m very proud to present the excellent results obtained using Cardiawave’s NIUT device to treat patients with severe symptomatic aortic valve stenosis, leading to a significant improvement in their condition and a better quality of life. This ACC.24 presentation represents a major contribution to the advance of science and will open up innovative therapeutic strategies for cardiology patients.”

A summary of the poster session will be published on the Journal of the American College of Cardiology’s website.

Presentation title: QUALITY OF LIFE ASSESSMENT AT 30-DAYS FOLLOW-UP OF THE VALVOSOFT® PIVOTAL STUDY ON SEVERE AORTIC VALVE STENOSE PATIENTS" (control number 16930)

Time and date: April 8, 2024 - 9:32 a.m.–9:42 a.m. EDT

The results of the Cardiawave First-in-Human “Valvosoft® FIM Study” were published in The Lancet in November 2023:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01518-0/fulltext

About Cardiawave : www.cardiawave.com 

© Cardiawave, 2024

Contacts

Cardiawave
Olivier Pierron – Directeur Général
cw-ceo@cardiawave.com
+33 (0)1 55 26 82 17

Presse
Stéphanie Lentini
slentini@gmail.com
+33 (0)7 62 62 51 21

Industry:

Cardiawave SA

Release Versions
English

Contacts

Cardiawave
Olivier Pierron – Directeur Général
cw-ceo@cardiawave.com
+33 (0)1 55 26 82 17

Presse
Stéphanie Lentini
slentini@gmail.com
+33 (0)7 62 62 51 21

More News From Cardiawave SA

VALVOSOFT®, the First Non-Invasive Treatment for Severe Symptomatic Aortic Stenosis (sSAS) from Cardiawave Receives CE Marking

LEVALLOIS-PERRET, France--(BUSINESS WIRE)--Cardiawave, a pioneering medtech company developing non-invasive ultrasound therapy (NIUT) for aortic stenosis, has received CE Certificate for Valvosoft®, the world’s first non-invasive therapeutic alternative to treat Severe Symptomatic Aortic Stenosis (sSAS), a serious, degenerative and fast-growing disease due to population aging, which remains without a solution for many patients around the world. “Innovating to address unmet patient needs is at t...

Cardiawave Strengthens Leadership with Appointment of Jonathan Freeman as Board Chairman

PARIS & BOSTON--(BUSINESS WIRE)--Cardiawave, today announced the appointment of Jonathan Freeman, PhD, as Chairman of its Board of Directors....

Cardiawave Announces Positive 12-Month Results from Its “Valvosoft® FIM Study” and "Valvosoft® Pivotal Study" for the Treatment of Severe Symptomatic Aortic Stenosis (sSAS)

LEVALLOIS-PERRET, France--(BUSINESS WIRE)--Cardiawave SA, medtech company specialized in valvular heart disease, presented today at the EuroPCR Congress the 12-month results from its "Valvosoft® FIM Study" and "Valvosoft® Pivotal Study" evaluating its innovative non-invasive ultrasound therapy (NIUT) device for the treatment of Severe Symptomatic Aortic Stenosis (sSAS). Following two First-in-Human studies (40 patients) that demonstrated the safety and feasibility of the therapy, and a multicen...
Back to Newsroom